

## PHARMACY BENEFIT PRIOR AUTHORIZATION UPDATES

November 25th, 2022

Below are upcoming updates to pharmacy benefit medication prior authorization criteria for Community Health Choice's Marketplace plans.

Drug/Class	Effective Date	Overview
Linzess	2/1/2023	Updated to require trial of plecanatide (Trulance)
Tadliq	12/1/2022	Adding to formulary with PA
Zonisade	12/1/2022	Adding to formulary with PA
Orkambi	12/1/2022	Removing age requirement from PA form
Imbruvica (granules)	12/1/2022	Adding to formulary with PA
Pemazyre	12/1/2022	Adding new indication for myeloid/lymphoid neoplasms
Stelara	12/1/2022	Updating weight requirements
Retevmo	12/1/2022	Adding new indication for solid tumors and updating the indication for NSCLC
Promacta	2/1/2023	Updating prescriber requirement for immune thrombocytopenia
Esbriet	12/1/2022	Updating diagnosis criteria to allow use of transbronchial lung cryobiopsy